A Phase 3 interventional study of Pregabalin in Seizure Disorder, Partial, sponsored by Pfizer. Completed at 84 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-03-05.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
To determine long-term safety and efficacy of pregabalin in patients with partial seizures.
881 studies on the registry are indexed under Seizures; 143 are open to participants now.
This study's enrollment of 337 is above the median of 64 across 610 interventional studies indexed under Seizures.
Browse Seizures studies →Pfizer is the lead sponsor of 3,244 studies on the registry; 139 are open to participants now.
Of its 582 completed or terminated interventional studies of FDA-regulated products, 381 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Safety Efficacy
This study is completed, as verified in Mar 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Pfizer